Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis.

Autor:	Bennett JC; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: jbenne63@jhu.edu., Deloria Knoll M; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: mknoll2@jhu.edu., Kagucia EW; Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Coast, Kilifi, Kenya., Garcia Quesada M; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Zeger SL; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Hetrich MK; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Yang Y; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Herbert C; UMass Chan Medical School, Worcester, MA, USA., Ogyu A; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Cohen AL; Department of Immunizations, Vaccines and Biologicals, WHO, Geneva, Switzerland; Division of Bacterial Diseases, National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA., Yildirim I; Department of Pediatrics, Yale New Haven Children's Hospital, New Haven, CT, USA., Winje BA; Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway., von Gottberg A; Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Viriot D; French Public Health Agency, Saint-Maurice, France., van der Linden M; Reference Laboratory for Streptococci, Department of Medical Microbiology, University Hospital RWTH Aachen, Aachen, Germany., Valentiner-Branth P; Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark., Suga S; Infectious Disease Center and Department of Clinical Research, National Hospital Organization Mie Hospital, Tsu, Japan., Steens A; Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands., Skoczynska A; National Reference Centre for Bacterial Meningitis, National Medicines Institute, Warsaw, Poland., Sinkovec Zorko N; Communicable Diseases Centre, National Institute of Public Health, Ljubljana, Slovenia., Scott JA; Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Coast, Kilifi, Kenya., Savulescu C; Epidemiology Department, Epiconcept, Paris, France., Savrasova L; Institute of Public Health, Riga Stradins University, Riga, Latvia., Sanz JC; Regional Public Health Laboratory, General Directorate of Public Health, Madrid, Spain., Russell F; Centre for International Child Health, WHO Collaborating Centre for Research and Training in Child and Neonatal Health, University of Melbourne, Parkville, VIC, Australia; Murdoch Children's Research Institute, Parkville, VIC, Australia., Ricketson LJ; Department of Pediatrics, University of Calgary, Calgary, AB, Canada., Puentes R; Instituto de Salud Pública de Chile, Santiago, Chile., Nuorti JP; Department of Health Security, Finnish Institute for Health and Welfare, Helsinki, Finland; Health Sciences Unit, Faculty of Social Sciences, Tampere University, Tampere, Finland., Mereckiene J; Health Protection Surveillance Centre, Dublin, Ireland., McMahon K; Centre for Disease Control, Department of Health and Community Services, Darwin, NT, Australia., McGeer A; Toronto Invasive Bacterial Diseases Network and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada., Mad'arová L; National Reference Centre for Pneumococcal and Haemophilus Diseases, Regional Authority of Public Health, Banská Bystrica, Slovakia., Mackenzie GA; Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia; Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK; Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine, Banjul, The Gambia; New Vaccines Group, Murdoch Children's Research Institute, Parkville, VIC, Australia., MacDonald L; Public Health Scotland, Glasgow, UK., Lepp T; Department of Communicable Disease and Control and Health Protection, Public Health Agency of Sweden, Solna, Sweden., Ladhani SN; Immunisation and Countermeasures Division, UK Health Security Agency, London, UK., Kristinsson KG; Department of Clinical Microbiology, Landspitali-The National University Hospital, Reykjavik, Iceland., Kozakova J; National Institute of Public Health, Prague, Czech Republic., Klein NP; Vaccine Study Center, Kaiser Permanente, Oakland, CA, USA., Jayasinghe S; National Centre for Immunisation Research and Surveillance and Discipline of Child and Adolescent Health, Children's Hospital Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Westmead, NSW, Australia., Ho PL; Department of Microbiology and Carol Yu Centre for Infection, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China., Hilty M; Swiss National Reference Centre for Invasive Pneumococci, Institute for Infectious Diseases, University of Bern, Bern, Switzerland., Heyderman RS; Malawi Liverpool Wellcome Programme, Blantyre, Malawi; NIHR Global Health Research Unit on Mucosal Pathogens, Division of Infection and Immunity, University College London, London, UK., Hasanuzzaman M; Child Health Research Foundation, Dhaka, Bangladesh., Hammitt LL; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Coast, Kilifi, Kenya., Guevara M; CIBER Epidemiology and Public Health, Madrid, Spain; Public Health Institute of Navarre-IdiSNA, Pamplona, Spain., Grgic-Vitek M; Communicable Diseases Centre, National Institute of Public Health, Ljubljana, Slovenia., Gierke R; Division of Bacterial Diseases, National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA., Georgakopoulou T; Department for Vaccine Preventable Diseases, National Public Health Organization, Athens, Greece., Galloway Y; Epidemiology Team, Institute of Environmental Science and Research, Wellington, New Zealand., Diawara I; Mohammed VI University of Sciences and Health, Mohammed VI Higher Institute of Biosciences and Biotechnologies (UM6SS), Casablanca, Morocco; Infectious Diseases Research Unit, Mohammed VI Center for Research and Innovation (CM6RI), Rabat, Morocco., Desmet S; Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium; National Reference Centre for Streptococcus Pneumoniae, University Hospitals Leuven, Leuven, Belgium., De Wals P; Department of Social and Preventive Medicine, Laval University, Quebec, QC, Canada., Dagan R; The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel., Colzani E; European Centre for Disease Prevention and Control, Solna, Sweden., Cohen C; Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Ciruela P; CIBER Epidemiology and Public Health, Madrid, Spain; Surveillance and Public Health Emergency Response, Public Health Agency of Catalonia, Barcelona, Spain., Chuluunbat U; National Center of Communicable Diseases, Ministry of Health, Ulaanbaatar, Mongolia., Chan G; Singapore Ministry of Health, Communicable Diseases Division, Singapore., Camilli R; Department of Infectious Diseases, Italian National Institute of Health, Rome, Italy., Bruce MG; Arctic Investigations Program, Division of Infectious Disease Readiness and Innovation, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, AK, USA., Brandileone MC; National Laboratory for Meningitis and Pneumococcal Infections, Center of Bacteriology, Institute Adolfo Lutz, São Paulo, Brazil., Bigogo G; Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya., Ampofo K; Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Utah Health Sciences Center, Salt Lake City, UT, USA., O'Brien KL; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Feikin DR; Department of Immunizations, Vaccines and Biologicals, WHO, Geneva, Switzerland., Hayford K; Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Jazyk:	angličtina
Zdroj:	The Lancet. Infectious diseases [Lancet Infect Dis] 2024 Dec 17. Date of Electronic Publication: 2024 Dec 17.
DOI:	10.1016/S1473-3099(24)00665-0
Abstrakt:	Background: Pneumococcal conjugate vaccines (PCVs) that are ten-valent (PCV10) and 13-valent (PCV13) became available in 2010. We evaluated their global impact on invasive pneumococcal disease (IPD) incidence in all ages. Methods: Serotype-specific IPD cases and population denominators were obtained directly from surveillance sites using PCV10 or PCV13 in their national immunisation programmes and with a primary series uptake of at least 50%. Annual incidence rate ratios (IRRs) were estimated comparing the incidence before any PCV with each year post-PCV10 or post-PCV13 introduction using Bayesian multi-level, mixed-effects Poisson regressions, by site and age group. All site-weighted average IRRs were estimated using linear mixed-effects regression, stratified by product and previous seven-valent PCV (PCV7) effect (none, moderate, or substantial). Findings: Analyses included 32 PCV13 sites (488 758 cases) and 15 PCV10 sites (46 386 cases) in 30 countries, primarily high income (39 sites), using booster dose schedules (41 sites). By 6 years after PCV10 or PCV13 introduction, IPD due to PCV10-type serotypes and PCV10-related serotype 6A declined substantially for both products (age <5 years: 83-99% decline; ≥65 years: 54-96% decline). PCV7-related serotype 19A increases before PCV10 or PCV13 introduction were reversed at PCV13 sites (age <5 years: 61-79% decline relative to before any PCV; age ≥65 years: 7-26% decline) but increased at PCV10 sites (age <5 years: 1·6-2·3-fold; age ≥65 years: 3·6-4·9-fold). Serotype 3 IRRs had no consistent trends for either product or age group. Non-PCV13-type IPD increased similarly for both products (age <5 years: 2·3-3·3-fold; age ≥65 years: 1·7-2·3-fold). Despite different serotype 19A trends, all-serotype IPD declined similarly between products among children younger than 5 years (58-74%); among adults aged 65 years or older, declines were greater at PCV13 (25-29%) than PCV10 (4-14%) sites, but other differences between sites precluded attribution to product. Interpretation: Long-term use of PCV10 or PCV13 reduced IPD substantially in young children and more moderately in older ages. Non-vaccine-type serotypes increased approximately two-fold to three-fold by 6 years after introduction of PCV10 or PCV13. Continuing serotype 19A increases at PCV10 sites and declines at PCV13 sites suggest that PCV13 use would further reduce IPD at PCV10 sites. Funding: Bill & Melinda Gates Foundation as part of the WHO Pneumococcal Vaccines Technical Coordination Project. Competing Interests: Declaration of interests KH reports employment at Pfizer from Oct 26, 2020. MDK reports grants from Merck and Pfizer, and personal fees from Merck. JAS reports grants from the Bill & Melinda Gates Foundation, the Wellcome Trust, the UK Medical Research Council, and the National Institute of Health Research. M-CCB reports lecture fees from MSD. ASk reports grants and personal fees from MSD and Pfizer. MvdL reports support from, membership on advisory boards for, and speakers honoraria from Pfizer and Merck. SD reports a grant from Pfizer. KA reports a grant from Merck. AvG reports research funding from Pfizer, and attendance at advisory board meetings for Pfizer and Merck. AM reports research support to her institution from Pfizer and Merck, and honoraria for advisory board membership from GSK, Merck, and Pfizer. SNL performs contract research for GSK, Pfizer, and Sanofi Pasteur on behalf of St George's University of London, with no personal remuneration. IY reports membership of an mRNA-1273 study group, and funding to her institution to conduct clinical research from BioFire, MedImmune, Regeneron, PaxVax, Pfizer, GSK, Merck, Novavax, Sanofi Pasteur, and Micron. RD reports grants or research support from Pfizer, MSD, and Medimmune; scientific consultancy for Pfizer, MeMed, MSD, and BiondVax; participation on advisory boards of Pfizer, MSD, and BiondVax; and being a speaker for Pfizer. LLH reports research grants to her institution from GSK, Pfizer, and Merck. JK reports an unrestricted grant-in-aid from Pfizer Canada. MHi reports reimbursement for advisory boards from MSD; and an investigator-initiated research grant from Pfizer paid to his institution. JCS reports assistance from Pfizer for attending scientific meetings. NPK reports research support from Pfizer, GSK, Sanofi Pasteur, Merck, and Protein Sciences (now Sanofi Pasteur). CC reports research support to her institution from Sanofi Pasteur. KGK reports grants from GSK. All other authors declare no competing interests. (Copyright © 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu